Basis of Presentation (Details Textual) - USD ($) |
1 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Apr. 13, 2016 |
Jan. 13, 2016 |
May 15, 2015 |
Jul. 24, 2017 |
Jan. 25, 2016 |
Jun. 30, 2017 |
Jun. 30, 2016 |
Jun. 30, 2015 |
Nov. 20, 2014 |
|
| Basis of Presentation [Line Items] | |||||||||
| Accumulated deficit | $ (72,123,000) | $ (57,591,000) | |||||||
| Net Cash Used in Operating Activities | $ (13,163,000) | (8,072,000) | |||||||
| Stock Issued During Period, Shares, New Issues | 6,500,000 | ||||||||
| Stock Issued During Period, Value, New Issues | $ 4,043,000 | $ 1,000,000 | $ 6,220,000 | ||||||
| Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |||||||
| Class Of Warrants Or Rights Exercised | 0 | 1,904,000 | |||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0 | $ 1.63 | |||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | $ (16,139,000) | $ (10,657,000) | |||||||
| Common Stock, Shares, Issued | 1,200,000 | 89,118,510 | 89,109,410 | ||||||
| Registration Payment Arrangement, Maximum Potential Consideration | $ 100,000,000 | ||||||||
| Eastern Affiliate [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Noncontrolling Interest, Description | Prior to the issuance of the shares of common stock pursuant to the purchase agreements with Eastern, Eastern beneficially owned approximately 30% of the Companys common stock, as reported in the Companys Annual Report on Form 10-K for the fiscal year ended June 30, 2015, filed with the SEC on October 13, 2015, calculated in accordance with the SECs beneficial ownership rules. As of the closing of the purchase agreements with Eastern and the simultaneous exercise by Eastern of its warrants to purchase iBio common stock, Eastern beneficially owned approximately 38% of the Companys outstanding shares of common stock. As of the filing date of this report, Eastern owns approximately 36.4% of the Companys outstanding common stock. See Note 11 in the consolidated financial statements | ||||||||
| Aspire Capital Fund Llc [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Stock Issued During Period, Shares, New Issues | 200,000 | ||||||||
| Stock Issued During Period, Value, New Issues | $ 500,000 | ||||||||
| Aspire Capital Fund Llc [Member] | Maximum [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Sale of Stock, Consideration Received on Transaction | $ 15,000,000 | ||||||||
| iBio CMO [Member] | Eastern [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Stock Issued During Period, Shares, New Issues | 3,500,000 | ||||||||
| Stock Issued During Period, Shares, Acquisitions | 10,000,000 | ||||||||
| Common Stock, Par or Stated Value Per Share | $ 0.622 | ||||||||
| Class Of Warrants Or Rights Exercised | 1,784,000 | ||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.53 | ||||||||
| Lincoln Park Capital Fund, LLC [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Aggregate Common Stock Purchased | $ 16,000,000 | ||||||||
| Stock Issued During Period, Shares, New Issues | 2,500,000 | ||||||||
| Stock Issued During Period, Value, New Issues | $ 1,000,000 | ||||||||
| Common Stock, Shares, Issued | 1,200,000 | ||||||||
| iBio CDMO [Member] | Eastern Affiliate [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Related Party Transaction, Description of Transaction | The Eastern Affiliate contributed $15 million in cash for a 30% interest in the Companys subsidiary iBio CDMO LLC (iBio CDMO). The Company retained a 70% interest in iBio CDMO and contributed a royalty bearing license which grants iBio CDMO a non-exclusive license to use the Companys proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Companys iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns 99.99% of iBio CDMO. | ||||||||
| iBio CDMO [Member] | Eastern [Member] | |||||||||
| Basis of Presentation [Line Items] | |||||||||
| Stock Issued During Period, Shares, Acquisitions | 10,000,000 | ||||||||
| Proceeds From Capitalization Received | $ 15,000,000 | ||||||||
| Stock Issued During Period, Value, Acquisitions | $ 7,200,000 | ||||||||